Quad 2 (HIV)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 8
3 Disease Overview 10
3.1 Etiology and Pathophysiology 10
3.1.1 Etiology 10
3.1.2 Pathophysiology 13
3.1.3 Prognosis 13
3.1.4 Quality of Life 14
3.2 Symptoms 14
3.2.1 Primary or Acute Infection 14
3.2.2 Chronic Infection 14
3.2.3 Advanced Infection/AIDS 15
4 Disease Management 16
4.1 Treatment Overview 16
5 Competitive Assessment 20
5.1 Overview 20
5.2 Strategic Competitor Assessment 20
6 Opportunity and Unmet Need 23
6.1 Overview 23
6.1.1 Simplified regimens and dosing frequency 23
6.1.2 Side effects and toxicities 24
6.1.3 Drug resistance 24
6.1.4 Prophylaxis 25
6.1.5 Lack of functional cure 25
6.1.6 Patient awareness 26
6.1.7 Treatment availability 26
6.1.8 Treatment affordability 27
6.2 Unmet Needs Gap Analysis 27
6.3 Opportunities 29
6.3.1 Development of treatments to counter drug resistance 29
6.3.2 Collaborations to develop newer STRs 29
6.3.3 Development of new injectable formulations 29
6.3.4 Development of new prophylactics 30
6.3.5 Development of drugs that use a novel mechanism of action 30
6.3.6 Public-Private Partnerships 30
7 Pipeline Assessment 31
7.1 Overview 31
7.2 Promising Drugs in Clinical Development 32
8 Quad 2 35
8.1 Overview 35
8.2 Efficacy 37
8.3 Safety 38
8.4 Dosing and Formulation 38
8.5 Potential Clinical Positioning 38
8.6 Potential Commercial Positioning 38
8.7 Pricing and Reimbursement 39
8.8 SWOT Analysis 39
8.9 Forecast 41
9 Appendix 42
9.1 Bibliography 42
9.2 Abbreviations 46
9.3 Methodology 48
9.4 Forecasting Methodology 48
9.4.1 HIV Prevalence 48
9.4.2 Percent Drug-Treated Patients 48
9.4.3 General Pricing Assumptions 49
9.4.4 Generic Erosion 50
9.4.5 Pricing of Pipeline agents 50
9.5 Physicians and Specialists Included in this Study 51
9.5.1 Survery of Prescribing Physicians 52
9.6 About the Authors 53
9.6.1 Authors 53
9.6.2 Global Head of Healthcare 54
9.7 About GlobalData 55
9.8 Contact Us 55
9.9 Disclaimer 55